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 is overexpressed in the adipose tissue of obese ro-
dents and humans, and is associated with insulin resistance.
To more closely link TNF expression with whole body insu-
lin action, we examined the expression of TNF by muscle,
which is responsible for the majority of glucose uptake in
vivo. Using RT-PCR, TNF was detected in human heart, in
skeletal muscle from humans and rats, and in cultured hu-
man myocytes. Using competitive RT-PCR, TNF was quan-
titated in the muscle biopsy specimens from 15 subjects
whose insulin sensitivity had been characterized using the
glucose clamp technique. TNF expression in the insulin re-
sistant subjects and the diabetic patients was fourfold
higher than in the insulin sensitive subjects, and there was a
significant inverse linear relationship between maximal glu-





















In nine subjects, muscle cells from vastus lateralis muscle
biopsies were placed into tissue culture for 4 wk, and in-
duced to differentiate into myotubes. TNF was secreted into
the medium from these cells, and cells from diabetic pa-
tients expressed threefold more TNF than cells from non-
diabetic subjects. Thus, TNF is expressed in human muscle,
and is expressed at a higher level in the muscle tissue and in
the cultured muscle cells from insulin resistant and diabetic
subjects. These data suggest another mechanism by which
TNF may play an important role in human insulin resis-
tance. (
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The development of obesity is not completely understood; hu-
mans gain weight to variable degrees when presented with ex-
cess calories (1, 2), suggesting that individuals can defend
against obesity. In addition, insulin resistance accompanies
nearly all patients who become obese, yet the relationship be-
tween adiposity and insulin sensitivity is not clear. One possi-
ble etiology for the insulin resistance of obesity is the produc-














adipose tissue and demonstrated higher expression in the adi-
pose tissue of insulin resistant, genetically obese rodents (3, 4).
These observations in rodents were essentially confirmed by
recent human studies, which demonstrated elevated TNF ex-
pression in the adipose tissue of obese subjects, and decreased










function in an autocrine fashion to regulate insulin sensitivity
in adipocytes. In an attempt to reverse insulin resistance, a sol-








rats, resulting in an increase in insulin-stimulated glucose up-
take, along with an increase in autophosphorylation of the in-
sulin receptor and insulin receptor substrate 1 (IRS-1) (3, 8).
These studies lead to several provocative conclusions re-
garding the interactions between adipose tissue and muscle.
Adipose tissue expressed higher levels of TNF, and the anti-
TNF infusion in the animals resulted in an increase in glucose
disposal (3). Because muscle accounts for most in vivo glucose
disposal (9), these data suggested that muscle responded to
anti-TNF treatment. In addition, the anti-TNF infusion re-
sulted in an improvement in insulin receptor phosphorylation
in both adipose tissue and muscle (10). There are several possi-
bilities for these effects on muscle. As suggested by Hotamis-
ligil and Spiegelman (4), TNF produced by the adipose tissue
in, or surrounding, muscle may have caused insulin resistance
in muscle, and this peri-muscular adipose TNF may have been
inhibited by the anti-TNF antibodies. On the other hand, mus-
cle, like adipose tissue, may itself express TNF, which would
then function in an autocrine fashion to inhibit insulin action.
As described herein, we have successfully measured TNF
expression in human and rat muscle, and demonstrate regula-
tion of muscle TNF during changes in insulin sensitivity. These
studies suggest another potential mechanism for the increased




Patients and sample acquisition. 
 
Patients were recruited from the
outpatient clinics of the Indiana University School of Medicine, the
La Jolla VA Medical Center, and Cedars-Sinai Medical Center. This
protocol was approved by each institution’s respective IRB, and all
subjects gave informed consent to the procedures. The characteristics
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of the patients are shown in Tables I and II. In some of the patients,
insulin sensitivity was characterized using the hyperinsulinemic eu-
glycemic clamp technique, as described previously (11, 12). In brief,
the glucose disposal rate was calculated on the basis of the glucose in-


















), corrected for changes in glucose pool size. Hepatic glu-
cose output was assumed to be completely suppressed at the high in-
sulin infusion rate (12). In all subjects, the studies were carried out for
at least 3 h, and the glucose infusion rate was stable for the final 60
min of the study. Glucose disposal rates were normalized per kilo-
gram of lean body mass, determined by dual energy x-ray absorpti-
ometry scanning. During the steady-state period, the serum glucose





 4%. Muscle biopsies were performed in subjects character-





these subject groups are described in Table II. Euglycemic clamp data
were not available on the nine subjects recruited for muscle cell cul-
tures, and these subject groups are described in Table I.
The human skeletal muscle samples were all obtained in the fast-
ing state by needle biopsy of the vastus lateralis muscle and immedi-
ately frozen in liquid nitrogen. Human heart was obtained from the
left ventricular myocardium (interventricular septum, to avoid con-
tamination by epicardial fat) of the explanted heart of transplant re-
cipients. Cell lines (Chinese hamster ovary [CHO], and L6 muscle
cells) were obtained from the American Type Culture Collection
(Rockville, MD).
 
Cultured human muscle cells. 
 
Cultured cells from human skele-





-Sk; Clonetics, San Diego, CA) and
differentiated into myotubes by the addition of 2% FBS after cells
reached 70% confluence, according to the instructions supplied by
Clonetics. In addition, myocytes were obtained by primary culture
from human muscle biopsies, as described previously (13). In brief,
each muscle biopsy yielded 250–400 mg of tissue, which was minced
and dissociated with three trypsin/EDTA treatments. Cells were pel-
leted and resuspended in medium (SkGM; Clonetics) with 2% FBS




 environment. After reaching 70–80% con-
fluence, these cells were induced to form fused myotubes by changing
the medium to DME containing 2% FBS. Previous studies using fluo-
rescent cell sorting, using an antibody directed against a muscle surface





myoblasts. In addition, these cells responded to insulin with an in-
crease in glucose transport and glycogen synthesis (13).
 
Measurement of TNF mRNA levels using reverse-transcriptase






To measure muscle TNF ex-
pression, a quantitative competitive PCR assay was developed, as de-
scribed previously (6). Total RNA was extracted from muscle accord-
ing to the method of Chomczynski and Sacchi (15), and the quality of
RNA was verified by ethidium bromide staining of rRNA bands on a
minigel. The primer sites for PCR were located at nucleotides 217 to
236, and 426 to 445 of the TNF cDNA. For rat muscle, as well as for
cell lines derived from rodents, slightly different primers were used.
The upstream primer was GCC ATT GGC CAG GAG GGC, and





of total RNA were added to increasing quantities of a cRNA con-
struct, which contained a 49-bp deletion (16). After the reverse tran-





resulting ethidium bromide-stained gel was imaged using an Image-
store 5000 scanner, and analyzed using the Gelbase/Gelblot software
(Ultraviolet Products, Ltd., San Gabriel, CA). The ratio of TNF
product/cRNA standard was plotted against the number of copies of
cRNA added, to yield the equivalence point between cRNA and





total RNA, where “number of copies” refers to the number of copies
of the cRNA added. PCR was negative when the reaction was per-
formed without prior RT reaction, indicating a lack of contamination.
 
Western blotting of TNF protein. 
 
TNF was identified in the me-
dium of cultured human muscle cells by Western blotting, using
methods described previously (6). Cells were grown to confluence
and differentiated into myocytes by the addition of DME containing
2% Fetal bovine serum. Serum-free medium was added and condi-
tioned medium was collected 2 h later. Medium was concentrated
10-fold using Centricon Concentrators (Centricon-3; Amicon, Inc.,
Beverly, MA), and was then analyzed under denaturing conditions on
a 15% SDS polyacrylamide gel. After transfer to nitrocellulose, the
membrane was blotted with a 1:2,000 dilution of rabbit anti-TNF anti-
serum (generously provided by Dr. Carl Grunfeld), followed by
biotinylated anti–rabbit IgG (Sigma Chemical Co.), and streptavidin-
peroxidase (Promega, Madison, WI). The blot was developed with a
chemoluminescent peroxidase substrate (Promega). Quantitation
was performed by scanning the blot, and comparison with the West-




All data were analyzed non-parametrically, using the
Wilcoxon matched-paired sign rank test for paired data, and the
Mann-Whitney test for non-paired data. Linear regressions were per-




To determine whether TNF was expressed in human muscle,
RNA was extracted from a variety of muscle sources and RT-
PCR was performed as described in Methods. As shown in
Fig. 1, the predicted 229-base fragment for TNF was detected
in human skeletal and heart muscle, as well as in rat skeletal
muscle. Because muscle contains other cells besides myocytes,
TNF mRNA was measured in cultured myocytes. As shown in
Fig. 1, the TNF mRNA was detected in cultured myoblasts, as
well as in myocytes cultured from human muscle biopsies, as
described in Methods. Cells that contained no detectable TNF
using these methods included L6 cells, which is a rat muscle
cell line, and CHO cells.
Fig. 2 illustrates the use of quantitative RT-PCR for the
measurement of TNF mRNA from cultured myocytes. RNA
was extracted from myocytes prepared from control and dia-




Abbreviations used in this paper:
 
 BMI, body mass index; GDR, glu-
cose disposal rate; NIDDM, non-insulin dependent diabetes mellitus;
RT, reverse transcriptase. 
Figure 1. TNF mRNA in muscle cells and tissue. Using RT-PCR, the 
predicted 229-bp TNF fragment was demonstrated in total RNA ex-
tracted from human skeletal and heart muscle, rat muscle (soleus), 
cultured human myoblasts and cultured myocytes from human mus-
cle biopsies (see Methods). Negative controls included CHO cells, 
and L6 cells.
 




cRNA, followed by RT-PCR. The PCR products derived from
the cRNA and TNF mRNA were easily distinguished on the
gel, and the ratio of the two products increased linearly with
addition of cRNA to the reaction. The equivalence point, at
which the amount of added cRNA-product was equal to the





g of total RNA, where “number of cop-
ies” refers to the number of copies of the cRNA added. As can
be seen, the amount of TNF mRNA in the myocytes from the
diabetic patient was higher than the TNF mRNA in the nor-
mal subject.
Additional subjects were recruited for muscle biopsy and
subsequent primary culture of myocytes. The description of
these nine subjects (5 nondiabetic and 4 diabetic) is shown in
Table I. There was no difference in body mass index (BMI) be-





C, and insulin levels were higher in the diabetics, as ex-
pected. After muscle biopsy, cells were placed into culture for
4 wk, and then differentiated into fused myotubes, as de-
scribed in Methods. TNF mRNA expression was measured us-
ing RT-PCR, as described above. As shown in Fig. 3, myocytes
cultured from diabetic patients contained significantly more
TNF mRNA than myocytes from nondiabetic subjects. To
demonstrate that the TNF protein was produced by these cells,
the conditioned medium from these cells was collected, con-





), the 17-kD TNF band was identified from the cultured
human muscle cells. In addition to the 17-kD band, a faster-
migrating species was identified, which probably represented
TNF breakdown product. The Western blot images were
scanned and compared to the TNF standard on the gel. Me-




0.01 ng/ml in cultures




0.55 ng/ml in cul-









In addition to measuring TNF in cultured myocytes, TNF
was measured in the muscle tissue of 15 subjects, who covered
a spectrum of insulin sensitivity, as defined by euglycemic
clamping. As shown in Table II, five of these subjects were in-
sulin sensitive, with a mean, maximally stimulated glucose dis-




0.7 mg/kg per minute, whereas five





0.5 mg/kg per minute), and five subjects had non–





1.5 mg/kg per minute). As expected, the in-
sulin resistant and diabetic subjects had higher fasting insulin
levels, and the diabetic subjects had higher fasting blood glu-
cose levels, and were more obese.
Figure 2. Quantitation of TNF mRNA in muscle using RT-PCR. To-
tal RNA was extracted from myocytes cultured from a normal sub-
ject, and a subject with diabetes. (A) Total RNA from each culture 
was added to increasing quantities (as indicated) of a cRNA construct 
that contained primer sites for human TNFa. RT-PCR of this cRNA 
construct yielded a product that was 49 nucleotides shorter than the 
PCR product generated from native human TNFa mRNA, and which 
could therefore be distinguished on the gel. (B) The ratio of cRNA 
standard/TNF product was plotted against the number of copies of 
cRNA added, to yield the equivalence point between cRNA and 
TNF mRNA. This figure is the plot of the gels from A. The equiva-
lence point for the normal (nondiabetic) subject was 4.2 3 103 copies, 
and for the diabetic patient the equivalence point was 27 3 103 cop-
ies, which refers to the number of copies of the cRNA added. Data 
were expressed as the “number of copies”/mg of total RNA, which 
yielded the values shown (7.97 3 103, and 54.9 3 103 copies/mg total 
RNA for normal and diabetic, respectively).
Figure 3. TNF mRNA levels in myocytes cultured from muscle biop-
sies of normal and diabetic subjects. Data are expressed in relation to 
copies of cRNA added/mg total RNA. (Inset) TNF secretion into the 
medium. Western blot of TNF from cultured muscle cells. Purified 
TNF (1 ng) is shown alongside the medium from myocyte cultures 







TNF mRNA levels were measured from the muscle biopsy
specimens from each subject. As shown in Fig. 4, TNF mRNA
levels were significantly higher in both the insulin resistant
subjects, and the diabetic subjects. When the relationship be-
tween in vivo insulin action, as represented by the maximal
glucose disposal rate, and muscle TNF expression was ana-
lyzed, there was a significant linear relationship. As shown in
Fig. 5, increasing muscle TNF expression was associated with a





















Thus, there was increased expression of TNF in both cultured





TNF is a cytokine produced in large quantities by macro-
phages, and has long been associated with the cachexia of can-
cer and AIDS because of its many catabolic actions (17). In
adipocytes, these catabolic actions include a decrease in the ac-
tivity of lipoprotein lipase (LPL) (18, 19), a decrease in the ex-
pression of the glucose transporter Glut4 (20), and an increase
in lipolysis, suggesting an increase in the activity of hormone
sensitive lipase (21). Recent studies have demonstrated that
TNF is expressed in adipose tissue, and is expressed at higher
levels in the adipose tissue of obese rodents and humans (3, 5,
6). Therefore, the production of TNF by adipose tissue could
be a local regulator of fat cell size, and the overproduction of
TNF in the adipocytes of obese mammals could limit adipo-
cyte size through some combination of catabolic actions.
Additional studies have suggested that TNF is important in
the development of insulin resistance, both in obesity, and in









 rats, which have high levels of adipose tissue TNF,
there was a 2–3-fold increase in insulin-stimulated glucose up-
take, along with improved insulin receptor autophosphoryla-
tion in both adipose tissue and muscle (3, 10). Since muscle is
the main determinant of insulin-stimulated glucose uptake,
these findings indicated that the systemic inhibition of TNF af-
fected in vivo insulin action, and therefore likely involved insu-
lin action in muscle. There are several possibilities to explain
these changes involving muscle. Adipose tissue TNF may be
secreted into plasma, and plasma TNF may affect muscle insu-
lin responsiveness. However, TNF levels in plasma are very
low, and cannot be reproducibly measured, even in patients
with obesity or metastatic cancer (5, 17, 22). Therefore, adi-
pose TNF may not affect muscle in a traditional humoral fash-
ion. Another possibility is an indirect effect, where adipose
TNF triggers other events, which ultimately lead to decreased
muscle insulin action. It is also possible that certain adipose tis-
sue depots, which are in close proximity to muscle, secrete
TNF, which then affect muscle glucose transport in a paracrine
fashion (4).
As described herein, TNF was expressed by both rat and
human muscle, and was also expressed by muscle cells in cul-
ture. These data suggest that TNF could have been produced
by muscle cells and functioned in an autocrine fashion to in-
hibit muscle glucose transport. Hence, when TNF binding pro-








 rats (3, 10), it may have inhibited
muscle TNF, as well as inhibit TNF from other sources, such as
adipose tissue. However, in a previous study, TNF mRNA was
not detected in rat muscle by Northern blot (3). We demon-
strated the presence of both the TNF mRNA, as well as the
TNF protein in cultured cells. The TNF detected in muscle
could not have been from contamination from adipose cells.
TNF was detected in heart muscle and rat skeletal muscle,
both of which were free of adipose tissue, and in cultured mus-





myocytes (13), it is possible that the cell of origin for TNF ex-
pression was a cell in muscle other than a myocyte. The level
of expression of TNF by muscle is lower than that in adipose
tissue, and therefore RT-PCR was used to measure TNF
mRNA levels in muscle.
TNF expression was increased in the muscle biopsy sam-
ples from subjects with insulin resistance, and there was a sig-
nificant inverse relationship between TNF mRNA levels and
GDR. It is important to note that muscle TNF was increased in
insulin resistant non-diabetics, as well as in subjects with estab-
lished NIDDM. Therefore, the elevated muscle TNF cannot
be a result of hyperglycemia and the diabetic milieu. This rela-
tionship between TNF and GDR was dependent on the inclu-
 










































































M/F Age GDR Insulin FBG BMI Body fat
 
















































































4.7 199.3635.5‡ 39.162.2‡ 37.864.5
*P , 0.05 vs. normal, insulin sensitive; ‡P , 0.02 vs. normal, insulin sensitive.
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sion of the normal, insulin sensitive subjects, as there was not a
significant correlation with TNF when just the insulin resistant
subjects were considered. In addition, TNF expression was
also elevated in muscle cells cultured from obese diabetics,
when compared to obese nondiabetics. The diabetic subjects
were likely more insulin resistant than the nondiabetic con-
trols, as evidenced by the elevated blood insulin levels. These
cells had been removed from the diabetic environment and in
culture for 4 wk, yet they still displayed elevated TNF.
It is tempting to speculate that disordered TNF regulation
in muscle may be an important part of insulin resistance. Al-
though the levels of TNF expression by muscle were low, they
may be sufficient to cause insulin resistance in an autocrine
manner in muscle. Because cultured muscle cells from diabet-
ics continued to express higher levels of TNF, and because in-
sulin resistant nondiabetics overexpressed TNF in muscle,
these data are consistent with TNF as a primary, or as an early
pathophysiologic marker of the insulin resistant state, and
could be part of the complex genetic syndrome characterized
phenotypically by obesity, insulin resistance, and NIDDM. On
the other hand, it is possible that the elevated TNF expression
is a response to the insulin resistant state, and that cells main-
tain this overexpression when cultured.
In summary, TNF was expressed by human muscle and myo-
cytes in culture, and TNF expression was higher in the muscle
of subjects with insulin resistance and NIDDM. These data
suggest an important role for TNFa in the pathogenesis of hu-
man insulin resistance, as occurs in obesity and diabetes.
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